239 related articles for article (PubMed ID: 36417488)
61. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.
Revill K; Wang T; Lachenmayer A; Kojima K; Harrington A; Li J; Hoshida Y; Llovet JM; Powers S
Gastroenterology; 2013 Dec; 145(6):1424-35.e1-25. PubMed ID: 24012984
[TBL] [Abstract][Full Text] [Related]
62. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.
Zheng B; Liu XL; Fan R; Bai J; Wen H; Du LT; Jiang GQ; Wang CY; Fan XT; Ye YN; Qian YS; Wang YC; Liu GJ; Deng GH; Shen F; Hu HP; Wang H; Zhang QZ; Ru LL; Zhang J; Gao YH; Xia J; Yan HD; Liang MF; Yu YL; Sun FM; Gao YJ; Sun J; Zhong CX; Wang Y; Kong F; Chen JM; Zheng D; Yang Y; Wang CX; Wu L; Hou JL; Liu JF; Wang HY; Chen L
Clin Cancer Res; 2021 Jul; 27(13):3772-3783. PubMed ID: 33947693
[TBL] [Abstract][Full Text] [Related]
63. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
[TBL] [Abstract][Full Text] [Related]
64. [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
Fan ZH; Ren F
Zhonghua Gan Zang Bing Za Zhi; 2022 Dec; 30(12):1382-1386. PubMed ID: 36891725
[TBL] [Abstract][Full Text] [Related]
65. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
66. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
67. Diagnostic Value of the Hypomethylation of the WISP1 Promoter in Patients with Hepatocellular Carcinoma Associated with Hepatitis B Virus.
Chen LM; Xiang L; Sun WJ; Zhai YJ; Gao S; Fan YC; Wang K
Tohoku J Exp Med; 2020 Dec; 252(4):297-307. PubMed ID: 33239483
[TBL] [Abstract][Full Text] [Related]
68. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
Wen Y; Han J; Chen J; Dong J; Xia Y; Liu J; Jiang Y; Dai J; Lu J; Jin G; Han J; Wei Q; Shen H; Sun B; Hu Z
Int J Cancer; 2015 Oct; 137(7):1679-90. PubMed ID: 25845839
[TBL] [Abstract][Full Text] [Related]
69. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
70. Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers.
Kao WY; Yang SH; Liu WJ; Yeh MY; Lin CL; Liu CJ; Huang CJ; Lin SM; Lee SD; Chen PJ; Yu MW
Mol Carcinog; 2017 Feb; 56(2):425-435. PubMed ID: 27254796
[TBL] [Abstract][Full Text] [Related]
71. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma.
Jain S; Chen S; Chang KC; Lin YJ; Hu CT; Boldbaatar B; Hamilton JP; Lin SY; Chang TT; Chen SH; Song W; Meltzer SJ; Block TM; Su YH
PLoS One; 2012; 7(4):e35789. PubMed ID: 22536438
[TBL] [Abstract][Full Text] [Related]
72. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.
Ji XF; Fan YC; Gao S; Yang Y; Zhang JJ; Wang K
World J Gastroenterol; 2014 Apr; 20(16):4723-9. PubMed ID: 24782625
[TBL] [Abstract][Full Text] [Related]
73. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma.
Zhao Y; Xue F; Sun J; Guo S; Zhang H; Qiu B; Geng J; Gu J; Zhou X; Wang W; Zhang Z; Tang N; He Y; Yu J; Xia Q
Clin Epigenetics; 2014; 6(1):30. PubMed ID: 25859288
[TBL] [Abstract][Full Text] [Related]
74. Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing.
Li J; Zhou X; Liu X; Ren J; Wang J; Wang W; Zheng Y; Shi X; Sun T; Li Z; Kang A; Tang F; Wen L; Fu W
Clin Chem; 2019 Jul; 65(7):916-926. PubMed ID: 31010820
[TBL] [Abstract][Full Text] [Related]
75. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.
Wang WW; Ang SF; Kumar R; Heah C; Utama A; Tania NP; Li H; Tan SH; Poo D; Choo SP; Chow WC; Tan CK; Toh HC
PLoS One; 2013; 8(7):e68904. PubMed ID: 23874805
[TBL] [Abstract][Full Text] [Related]
76. Clinical implications of DNA methylation in hepatocellular carcinoma.
Sceusi EL; Loose DS; Wray CJ
HPB (Oxford); 2011 Jun; 13(6):369-76. PubMed ID: 21609368
[TBL] [Abstract][Full Text] [Related]
77. Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.
Yu B; Zhou S; Liang H; Ye Q; Wang Y
Dig Dis Sci; 2022 Jun; 67(6):2283-2292. PubMed ID: 33982217
[TBL] [Abstract][Full Text] [Related]
78. Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach.
Gentilini D; Scala S; Gaudenzi G; Garagnani P; Capri M; Cescon M; Grazi GL; Bacalini MG; Pisoni S; Dicitore A; Circelli L; Santagata S; Izzo F; Di Blasio AM; Persani L; Franceschi C; Vitale G
Oncotarget; 2017 Jun; 8(26):41890-41902. PubMed ID: 28514750
[TBL] [Abstract][Full Text] [Related]
79. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
[TBL] [Abstract][Full Text] [Related]
80. Fragment length profiles of cancer mutations enhance detection of circulating tumor DNA in patients with early-stage hepatocellular carcinoma.
Nguyen VC; Nguyen TH; Phan TH; Tran TT; Pham TTT; Ho TD; Nguyen HHT; Duong ML; Nguyen CM; Nguyen QB; Bach HT; Kim VV; Pham TA; Nguyen BT; Nguyen TNV; Huynh LAK; Tran VU; Tran TTT; Nguyen TD; Phu DTB; Phan BHH; Nguyen QT; Truong DK; Do TT; Nguyen HN; Phan MD; Giang H; Tran LS
BMC Cancer; 2023 Mar; 23(1):233. PubMed ID: 36915069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
